People News: Affymax, Neogenix Oncology and ProBioGen AG

Share this article:

Affymax promoted Sylvia Wheeler to VP, corporate communications. Wheeler has more than 20 years of corporate communications and investor relations experience in the bioscience industry and is a member of the board of directors for the National Kidney Foundation Northwestern US Division.

Neogenix Oncology, Inc. has named Philip M. Arlen, MD its CEO. Arlen joined Neogenix as president and chief medical officer of the company in July 2008. Prior to 2008, he spent 11 years at the National Cancer Institute, USA, most recently as the director of the clinical research group for the Laboratory of Tumor Immunology and Oncology.

ProBioGen AG announced that Dr. Volker Sandig has been appointed to chief scientific officer (CSO) of the company. He will take over the duties of Dr. Uwe Marx, who will take an opportunity to lead an entrepreneurial innovation team at the Technical University Berlin.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media